NZ592357A - Oxidized lipid compounds and uses thereof - Google Patents

Oxidized lipid compounds and uses thereof

Info

Publication number
NZ592357A
NZ592357A NZ592357A NZ59235709A NZ592357A NZ 592357 A NZ592357 A NZ 592357A NZ 592357 A NZ592357 A NZ 592357A NZ 59235709 A NZ59235709 A NZ 59235709A NZ 592357 A NZ592357 A NZ 592357A
Authority
NZ
New Zealand
Prior art keywords
lipid compounds
oxidized lipid
oxidized lipids
compounds
solvates
Prior art date
Application number
NZ592357A
Other languages
English (en)
Inventor
Eti Kovalevski-Ishai
Zeev Ziniuk
Niva Yacov
Gideon Halperin
Erez Feige
Eyal Breitbart
Itzhak Mendel
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of NZ592357A publication Critical patent/NZ592357A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/26—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-nitrogen bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C07F9/106—Adducts, complexes, salts of phosphatides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4411—Amides of acyclic unsaturated acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pest Control & Pesticides (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Agronomy & Crop Science (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
NZ592357A 2008-11-06 2009-11-05 Oxidized lipid compounds and uses thereof NZ592357A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19322008P 2008-11-06 2008-11-06
PCT/IL2009/001049 WO2010052718A1 (en) 2008-11-06 2009-11-05 Oxidized lipid compounds and uses thereof

Publications (1)

Publication Number Publication Date
NZ592357A true NZ592357A (en) 2013-09-27

Family

ID=42152558

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592357A NZ592357A (en) 2008-11-06 2009-11-05 Oxidized lipid compounds and uses thereof

Country Status (14)

Country Link
US (2) US9206206B2 (enExample)
EP (3) EP2348866B1 (enExample)
JP (2) JP5752599B2 (enExample)
KR (1) KR20110095288A (enExample)
CN (2) CN104788492A (enExample)
AU (1) AU2009312355C1 (enExample)
CA (1) CA2740726A1 (enExample)
ES (1) ES2534044T3 (enExample)
HK (2) HK1206199A1 (enExample)
MX (1) MX2011004773A (enExample)
NZ (1) NZ592357A (enExample)
RU (2) RU2532546C2 (enExample)
WO (1) WO2010052718A1 (enExample)
ZA (1) ZA201102872B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
KR20110095288A (ko) * 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
WO2012119781A2 (en) * 2011-03-10 2012-09-13 University Of Geneva Novel lipids, phospholipids, phospholipid and lipid compositions and their use
SG11201400208PA (en) 2011-09-01 2014-03-28 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids
EP2791101B1 (en) * 2011-12-12 2019-09-18 Vascular Biogenics Ltd. Treatment of non-alcoholic steatohepatitis
CN106999506A (zh) 2014-11-26 2017-08-01 脉管生物生长有限公司 氧化脂质以及纤维化的治疗或预防
US9771385B2 (en) * 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
EP3735977A1 (en) * 2015-07-31 2020-11-11 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 and cancer
ES2963268T3 (es) * 2015-07-31 2024-03-26 Immunewalk Therapeutics Inc Proteína 2 que contiene el dominio de esperma móvil e inflamación
JP6755530B2 (ja) * 2016-09-02 2020-09-16 国立大学法人岩手大学 皮膚炎の予防又は治療用医薬組成物
WO2021199003A1 (en) * 2020-04-02 2021-10-07 Vascular Biogenics Ltd. Oxidized lipids and treatment or prevention of inflammation or infectious disease caused by coronavirus infection
JP7559223B2 (ja) 2020-08-24 2024-10-01 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物及びその使用
IL301202A (en) 2020-09-10 2023-05-01 Vascular Biogenics Ltd Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them
TWI925033B (zh) 2020-10-16 2026-05-11 美商基利科學股份有限公司 磷脂化合物及其用途
AU2023242443A1 (en) * 2022-03-28 2024-08-29 F. Hoffmann-La Roche Ag Synthesis of isomerically pure polyol-based phosphoramidites

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5638578B2 (enExample) 1973-05-18 1981-09-08
US4166132A (en) 1977-08-18 1979-08-28 Pfizer Inc. Antiviral amine derivatives of glycerol and propanediols
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) * 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
JPS5993022A (ja) * 1982-11-16 1984-05-29 Kao Corp ポリオ−ルエ−テル化合物およびその製造法ならびにこれを含有する化粧料
DE3307925A1 (de) 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4614796A (en) * 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (ja) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
JPS60104066A (ja) 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
AT383130B (de) 1984-05-15 1987-05-25 Chemie Linz Ag Verfahren zur herstellung von an c1 und c2 verschieden substituierten phosphatidylcholinen und phosphatidylethanolaminen ueber die neuen verbindungen 1-0-tritylglycerophosphocholin beziehungsweise (1-0,n-ditrityl)-glycerophosphoethanolamin
US4710579A (en) 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
JPH0617307B2 (ja) 1984-11-09 1994-03-09 武田薬品工業株式会社 抗腫瘍剤
US4827011A (en) * 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
EP0225129B1 (en) 1985-11-29 1989-05-24 Takeda Chemical Industries, Ltd. Phospholipid derivatives, their production and use
US5061626A (en) * 1986-03-24 1991-10-29 University Of Sydney Antigenic anarogues of platelet activating factor
EP0299972B1 (en) * 1986-04-07 1992-03-04 The Upjohn Company Anthelmintic quaternaryalkyl acylhydrazones, method of use and compositions
JPS6294A (ja) 1986-05-09 1987-01-06 Toyama Chem Co Ltd 新規なグリセロリン酸誘導体およびその塩並びにそれらの製造法
JPS6354386A (ja) 1986-08-26 1988-03-08 Takeda Chem Ind Ltd リン脂質およびその用途
JPS63135395A (ja) 1986-11-28 1988-06-07 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
US4970233A (en) * 1987-08-04 1990-11-13 Mchugh John E Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC)
DE3807123A1 (de) 1988-03-04 1989-09-14 Boehringer Mannheim Gmbh Substrate fuer phospholipasen
JPH01258691A (ja) 1988-04-06 1989-10-16 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
JP2534894B2 (ja) 1988-06-24 1996-09-18 日本ケミファ株式会社 新規なグリセリン誘導体およびその誘導体を含有する血圧降下剤
AU614636B2 (en) * 1988-07-21 1991-09-05 Ciba Specialty Chemicals Holding Inc. Corrosion inhibition
JPH0248585A (ja) 1988-08-10 1990-02-19 Nippon Oil & Fats Co Ltd リン脂質誘導体及びその製造方法
JPH03258740A (ja) 1990-03-06 1991-11-19 Kao Corp 液体油、その製造法及びこれを含有する化粧料
ES2019552A6 (es) 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
JP2869572B2 (ja) 1990-05-14 1999-03-10 和光純薬工業株式会社 ホスファチジルコリン誘導体の製造方法
JP3128782B2 (ja) * 1992-06-12 2001-01-29 科学技術振興事業団 架橋高分子薄膜の製造方法
US5561052A (en) * 1992-06-18 1996-10-01 Koike; Katsumasa Process for detecting oxidized lipids and process for forming oxidized lipids
FR2714382B1 (fr) * 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
AU1751795A (en) 1994-03-04 1995-09-18 University Of British Columbia, The Liposome compositions and methods for the treatment of atherosclerosis
JP3364313B2 (ja) * 1994-03-22 2003-01-08 株式会社トクヤマ ポルフィリン／インジウム錯体及び陰イオン感応膜
JPH0859545A (ja) * 1994-08-24 1996-03-05 Kao Corp カルボキシエチルエーテル誘導体及びこれを含有する洗浄剤組成物
AU3216695A (en) * 1994-08-29 1996-03-22 University Of North Carolina At Chapel Hill, The Lipid analogs for treating viral infections
JPH08208548A (ja) 1995-02-01 1996-08-13 Kao Corp グリセリン誘導体の製造法
US5660855A (en) * 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US6261597B1 (en) * 1995-08-31 2001-07-17 Seymour J. Kurtz Method for treating periodontal disease
DE19547022A1 (de) * 1995-12-15 1997-06-19 Boehringer Mannheim Gmbh Kovalente Lipid-Phosphonocarbonsäure-Konjugate, deren Herstellung sowie deren Verwendung als antivirale Arzneimittel
TW343975B (en) * 1995-12-15 1998-11-01 Boehringer Mannheim Gmbh New phospholipid derivatives of phosphonocarboxylic acids, the production thereof as well as their use as antiviral pharmaceutical agents
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
JP3781877B2 (ja) 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
WO2002053092A2 (en) 2001-01-04 2002-07-11 Vascular Biogenics Ltd. Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
US6414168B1 (en) * 1998-12-28 2002-07-02 Caschem, Inc. Epoxidation of ricinic compounds using a phase-transfer catalyst
US6348583B1 (en) * 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6670341B1 (en) * 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
JP4829454B2 (ja) 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
WO2001075168A1 (en) 2000-03-31 2001-10-11 The Regents Of The University Of California Control of a gene induced by oxidized lipids in human artery wall cells
IL156015A0 (en) 2000-11-24 2003-12-23 Vascular Biogenics Ltd Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7132559B2 (en) * 2001-02-27 2006-11-07 Trustees Of Tufts College Non-racemic hexafluoroleucine, and methods of making and using it
DE10155095A1 (de) 2001-11-09 2003-05-22 Cognis Deutschland Gmbh Alkyl(en)ylglycerinethercarbonsäuren
CN1526605A (zh) * 2003-09-23 2004-09-08 陈东明 一种水上游泳池
US7807847B2 (en) * 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
NZ553147A (en) * 2004-07-09 2010-07-30 Vascular Biogenics Ltd Improved process for the preparation of oxidized phospholipids
US20060194765A1 (en) * 2004-11-16 2006-08-31 Garcia Joe G N Methods and compositions using oxidized phospholipids
WO2007014001A2 (en) * 2005-07-21 2007-02-01 The Board Of Trustees Of The Leland Stanford Junior University Multiplex determination of lipid specific binding moieties
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US8137977B2 (en) * 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
JP2008037763A (ja) * 2006-08-01 2008-02-21 Adeka Corp 抗菌剤及び抗菌剤組成物
US9006217B2 (en) * 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) * 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
WO2009070298A1 (en) * 2007-11-28 2009-06-04 Teva Pharmaceutical Industries, Ltd. Method of delaying the onset of clinically definite multiple sclerosis
US8999960B2 (en) * 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
KR20110095288A (ko) * 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
MX338931B (es) 2010-01-05 2016-05-06 Vascular Biogenics Ltd Composiciones y metodo para tratar gliobastoma (gbm).
JP2013516455A (ja) * 2010-01-05 2013-05-13 バスキュラー バイオジェニックス リミテッド Ｖｂ−２０１を用いた治療
SG11201400208PA (en) 2011-09-01 2014-03-28 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids

Also Published As

Publication number Publication date
RU2532546C2 (ru) 2014-11-10
AU2009312355B2 (en) 2015-08-27
ZA201102872B (en) 2013-01-30
RU2014136085A (ru) 2016-03-27
EP2348866B1 (en) 2015-01-07
CA2740726A1 (en) 2010-05-14
EP2826370A2 (en) 2015-01-21
US20110207703A1 (en) 2011-08-25
EP2826369A3 (en) 2015-03-18
EP2348866A1 (en) 2011-08-03
MX2011004773A (es) 2011-06-21
CN102271517A (zh) 2011-12-07
JP2012507577A (ja) 2012-03-29
HK1155906A1 (en) 2012-06-01
EP2826370A3 (en) 2015-04-08
KR20110095288A (ko) 2011-08-24
US20130203707A1 (en) 2013-08-08
HK1206198A1 (en) 2016-01-08
EP2826369A2 (en) 2015-01-21
EP2348866A4 (en) 2012-04-11
WO2010052718A9 (en) 2011-06-16
CN104788492A (zh) 2015-07-22
JP5752599B2 (ja) 2015-07-22
AU2009312355A2 (en) 2011-05-12
AU2009312355A1 (en) 2010-05-14
HK1206199A1 (en) 2016-01-08
JP2015129157A (ja) 2015-07-16
CN102271517B (zh) 2015-04-08
US9206206B2 (en) 2015-12-08
AU2009312355C1 (en) 2016-02-18
ES2534044T3 (es) 2015-04-16
RU2011122729A (ru) 2012-12-20
WO2010052718A1 (en) 2010-05-14

Similar Documents

Publication Publication Date Title
JOP20210064B1 (ar) طريقة لانتاج ( z)-ألفا-فلورو-بيتا-أمينو-أكريل الدهيدات مستبدلة
MX2012003048A (es) Procesos para preparar derivados de bencil-benceno sustituidos con glucopiranosilo.
UA103794C2 (en) Liposome composition
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
ECSP10010434A (es) Inhibidores de hsp90
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
BR112014012221A2 (pt) método para produção de uma escova de dentes que tem uma cavidade interna
MY156319A (en) Spiroheterocyclic n-oxypiperidines as pesticides
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
EA201200209A1 (ru) Производные пиридина и пиразина в качестве модуляторов протеинкиназы
TN2013000347A1 (en) Production method of optically active dihydrobenzofuran derivative
IN2012DN02487A (enExample)
UY32108A (es) Compuestos de imidazol y de triazol, su uso, asi como productos que los contienen
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
UA102865C2 (ru) Вспомогательные вещества для таблетирования на основе лактозы и целлюлозы
WO2010041242A3 (en) Oxidized thiophospholipid compounds and uses thereof
TN2009000178A1 (en) Substituted pyrazole and triazole compounds as ksp inhibitors
MX2012007835A (es) Derivados de oxazolopirimidina sustituida en 2, 5,7.
MY149154A (en) Novel microbiocides
WO2013062964A3 (en) Methanol derivatives as trpv3 modulators
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
UY32100A (es) Compuestos de triazol, su uso asi, como productos que los contienen
UY33092A (es) Compuestos de triazol, su uso y agentes que los contienen
MX2012007837A (es) Derivados de oxazolopirimidina 2, 5 - sustituidos.
MY162945A (en) Azole derivative

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 NOV 2016 BY HENRY HUGHES

Effective date: 20140424

LAPS Patent lapsed